Daxor Corporation (NASDAQ:DXR) Short Interest Update

Daxor Corporation (NASDAQ:DXR) was the target of a large drop in short interest in June. As of June 15th, there was short interest totaling 2,083 shares, a drop of 66.2% from the May 31st total of 6,164 shares. Based on an average trading volume of 2,060 shares, the short-interest ratio is currently 1.0 days. Approximately 0.1% of the company’s stock are short sold.

Daxor Stock Performance

Shares of Daxor stock traded up $0.09 during trading on Monday, reaching $10.11. The company had a trading volume of 3,006 shares, compared to its average volume of 8,341. Daxor has a fifty-two week low of $8.56 and a fifty-two week high of $14.76. The firm’s fifty day moving average is $10.34 and its 200-day moving average is $11.47.

Daxor (NASDAQ:DXR) last posted its earnings results on Monday, March 2nd. The company reported ($0.10) earnings per share (EPS) for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “hold (c)” rating on shares of Daxor in a research report on Wednesday. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Osaic Holdings Inc. acquired a new position in shares of Daxor during the 2nd quarter worth about $86,000. Crescent Grove Advisors LLC bought a new stake in shares of Daxor in the 1st quarter valued at approximately $104,000. Nano Cap New Millennium Growth Fund L P acquired a new position in Daxor during the fourth quarter worth $184,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new stake in shares of Daxor during the 1st quarter worth about $245,000. Finally, Aristides Capital LLC acquired a new stake in shares of Daxor during the first quarter worth approximately $403,000. 1.34% of the stock is owned by institutional investors.

Daxor Company Profile

Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.

In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.